Bristol Myers Get Approval For Their Diabetes Drug

November 7th, 2010 - 8:09 pm ICT by Aishwarya Bhatt  

New York, Nov 7 (THAINDIAN NEWS) The Food and Drugs Administration in the United States has given the approval for AstraZeneca and Bristol-Myers Squibb to sell the diabetes drug, Onglyza in America. The drug’s approval comes amid concerns that the drug is linked to increase in the risk of heart related problems. However the FDA maintains that further tests are needed to confirm whether the drug indeed has cardiovascular concerns. The FDA was emphatic that the drug is not linked to increase risk of heart problems in low risk diabetes patients.

Onglyza’s arrival on the market is strategic because most of the diabetes drugs currently on the market are linked to weight gain and other complications in patients. If those complications are not linked to the drug, that will be very good for the market potential of the drug. Currently, Merck’s Januvia drug has the highest market share for diabetes drugs. In 2008, the company sold some $1.4 billion worth of the drug worldwide.

Onglyza is expected to reach the $1 Billion sales value anytime after 2011. It is the first drug that AstraZeneca is introducing to the market in seven years. The last drug that AstraZeneca introduced to the market was Crestor, which is a cholesterol fighter in the body.

Related Stories

Tags: , , , , , , , , , , , , , , , , , , ,

Posted in Business |

Subscribe